Evidence map›Paper›PMID 35393120›Full record

ReviewBiochemical pharmacology2022

Obesity I: Overview and molecular and biochemical mechanisms.

Robert H Lustig, David Collier, Christopher Kassotis, Troy A Roepke, Min Ji Kim, Etienne Blanc, Robert Barouki, Amita Bansal, Matthew C Cave, Saurabh Chatterjee and 8 more

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Biochemical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07560579 (Weight Loss and Endocrine Disrupting Chemicals), which is not on this map. Cited by 113 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 6 pooled it
19.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07560579 naactive not recruitingnot on this mapstarted 2025, after this paper: background citation

Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity

TypeinterventionalSponsorMillion Marker Wellness, Inc.Ran2025 to 2026Enrolled226ConditionsObesity &Amp, Amp, Amp, OverweightArmsEducational curriculum, Weight loss Application, Urinary EDC metabolite testing, Siphox clinic biomarker test, Weight loss reporting
3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 6 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Foods (Basel, Switzerland) · 2026
    Article
  11. Foods (Basel, Switzerland) · 2026
    Review
  12. Article
  13. Body mass index and gastrointestinal inflammation: Bio-molecular pathophysiology.World journal of gastrointestinal pathophysiology · 2026
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 14 institutions in 6 countries.

Robert H LustigDivision of Endocrinology, Department of Pediatrics, University of California, San Francisco, CA 94143, United States.
David CollierBrody School of Medicine, East Carolina University, Greenville, NC 27834, United States.
Christopher KassotisInstitute of Environmental Health Sciences and Department of Pharmacology, Wayne State University, Detroit, MI 48202, United States.
Troy A RoepkeSchool of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ 08901, United States.
Min Ji KimSorbonne Paris Nord University, Bobigny, INSERM U1124 (T3S), Paris, France.
Etienne BlancDepartment of Biochemistry and Toxicology, University of Paris, INSERM U1224 (T3S), 75006 Paris, France.
Robert BaroukiDepartment of Biochemistry and Toxicology, University of Paris, INSERM U1224 (T3S), 75006 Paris, France.
Amita BansalCollege of Health & Medicine, Australian National University, Canberra, Australia.
Matthew C CaveDivision of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY 40402, United States.
Saurabh ChatterjeeEnvironmental Health and Disease Laboratory, University of South Carolina, Columbia, SC 29208, United States.
Mahua ChoudhuryCollege of Pharmacy, Texas A&M University, College Station, TX 77843, United States.
Michael GilbertsonOccupational and Environmental Health Research Group, University of Stirling, Stirling, Scotland, United Kingdom.
Dominique Lagadic-GossmannUniv Rennes, INSERM, EHESP, IRSET - UMR_S 1085, 35000 Rennes, France.
Sarah HowardHealthy Environment and Endocrine Disruptor Strategies, Commonweal, Bolinas, CA 92924, United States.
Lars LindDepartment of Medical Sciences, University of Uppsala, Uppsala, Sweden.
Craig R TomlinsonNorris Cotton Cancer Center, Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, United States.
Jan VondracekDepartment of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.
Jerrold J HeindelHealthy Environment and Endocrine Disruptor Strategies, Commonweal, Bolinas, CA 92924, United States. Electronic address: jerryheindel@gmail.com.
Inserm · FRCommonweal · USAustralian National University · AUCzech Academy of Sciences, Institute of Biophysics · CZDartmouth College · USEast Carolina University · USRutgers, The State University of New Jersey · USSouth Carolina Department of Health and Environmental Control · USTexas A&M University · USUniversity of California, San Francisco · USUniversity of Louisville · USUniversity of Stirling · GBUppsala University · SEWayne State University · US

Funding

Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI BRIAN T BUCKLEY · 1988 to 2026
$47.4M
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ENOS, REILLY, NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
Translational Research Support CoreP30ES025128 · NIEHS · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Sue Fenton · 2015 to 2026
$18.3M
Superfund Training CoreP42ES023716 · NIEHS · UNIVERSITY OF LOUISVILLE · PI HEIN, DAVID W · 2017 to 2025
$18.1M
Use of Resveratrol to treat experimental multiple sclerosisP01AT003961 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI CHATTERJEE, SAURABH · 2007 to 2018
$14.2M
University of Louisville Center for Integrative Environmental Health SciencesP30ES030283 · NIEHS · UNIVERSITY OF LOUISVILLE · PI Amanda Jo LeBlanc · 2020 to 2026
$10.0M
UOFL ENVIRONMENTAL HEALTH SCIENCES TRAINING PROGRAMT32ES011564 · NIEHS · UNIVERSITY OF LOUISVILLE · PI David W Hein, John Pierce Wise · 2004 to 2026
$7.1M
The effects of climate change on the natural attenuation and sedimentary record of harmful algal bloom toxins and microbial signalsP01ES028942 · NIEHS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI CHATTERJEE, SAURABH · 2018 to 2022
$5.7M
Environmental Liver DiseaseR35ES028373 · NIEHS · UNIVERSITY OF LOUISVILLE · PI CAVE, MATTHEW C · 2017 to 2024
$4.0M
Sex differences in CRH signaling in the ovBNST underlie effects of chronic stressorsR01MH123544 · NIMH · RUTGERS, THE STATE UNIV OF N.J. · PI ROEPKE, TROY ADAM, SAMUELS, BENJAMIN A · 2020 to 2024
$2.4M
Exposome and Precision Medicine in NAFLDR01ES032189 · NIEHS · UNIVERSITY OF LOUISVILLE · PI CAVE, MATTHEW C · 2020 to 2022
$1.9M
NCCIH NIH HHS P01 AT003961NIDDK NIH HHS P30 DK063720NIEHS NIH HHS P01 ES028942NIEHS NIH HHS P30 ES005022NIEHS NIH HHS P30 ES025128NIEHS NIH HHS P30 ES030283NIEHS NIH HHS P42 ES023716NIEHS NIH HHS R00 ES030405NIEHS NIH HHS R01 ES032189NIEHS NIH HHS R21 ES031510NIEHS NIH HHS R35 ES028373NIEHS NIH HHS T32 ES011564NIGMS NIH HHS P20 GM103641NIMH NIH HHS R01 MH123544
6 · The paper itself

Abstract

Obesity is a chronic, relapsing condition characterized by excess body fat. Its prevalence has increased globally since the 1970s, and the number of obese and overweight people is now greater than those underweight. Obesity is a multifactorial condition, and as such, many components contribute to its development and pathogenesis. This is the first of three companion reviews that consider obesity. This review focuses on the genetics, viruses, insulin resistance, inflammation, gut microbiome, and circadian rhythms that promote obesity, along with hormones, growth factors, and organs and tissues that control its development. It shows that the regulation of energy balance (intake vs. expenditure) relies on the interplay of a variety of hormones from adipose tissue, gastrointestinal tract, pancreas, liver, and brain. It details how integrating central neurotransmitters and peripheral metabolic signals (e.g., leptin, insulin, ghrelin, peptide YY

Indexed as

LeptinObesityAdipocytesAdipose TissueEnergy MetabolismHumansInsulinInsulinLeptinAdipose tissueEnergy balanceHormone receptorsMetabolismMicrobiomeObesity

Identifiers

PMID35393120
PMCPMC9050949
OpenAlexW4223954920

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.